Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)
EventHumanCOVID-19Vaccines
Date
Location
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 18 March 2021.
Speakers:
The press briefing will be moderated by Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.